Novartis’ Exjade Label Expansion To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.
You may also be interested in...
Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.